Key Points
- Lynx1 Capital Management LP made multiple recent purchases of TCRX, totaling 161,801 shares at about $0.90 each (~$145,621), including a 75,500-share buy on Dec. 22, raising its stake to 8,012,916 shares (a 0.95% increase).
- TScan shares trade around $0.90 with a market cap of roughly $51.7M and a one-year range of $0.88–$3.43, trading below both the 50‑day and 200‑day moving averages.
- The company reported ($0.28) EPS and $2.51M revenue (beating estimates) but still shows very negative margins and ROE; analysts are mixed, with a consensus rating of "Hold" and a $6.60 target after several downgrades and price cuts.
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp purchased 75,500 shares of the business's stock in a transaction dated Monday, December 22nd. The stock was bought at an average cost of $0.90 per share, for a total transaction of $67,950.00. Following the purchase, the insider owned 8,012,916 shares in the company, valued at $7,211,624.40. This trade represents a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Lynx1 Capital Management Lp also recently made the following trade(s):
- On Tuesday, December 23rd, Lynx1 Capital Management Lp acquired 6,232 shares of TScan Therapeutics stock. The shares were purchased at an average price of $0.90 per share, with a total value of $5,608.80.
- On Friday, December 19th, Lynx1 Capital Management Lp purchased 80,069 shares of TScan Therapeutics stock. The stock was purchased at an average cost of $0.90 per share, with a total value of $72,062.10.
TScan Therapeutics Stock Up 1.1%
Shares of TScan Therapeutics stock opened at $0.91 on Wednesday. The company has a market capitalization of $51.68 million, a P/E ratio of -0.81 and a beta of 1.03. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. The business has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.62. TScan Therapeutics, Inc. has a 1 year low of $0.88 and a 1 year high of $3.43.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.07. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. As a group, equities analysts predict that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently commented on TCRX shares. BTIG Research downgraded TScan Therapeutics from a "buy" rating to a "neutral" rating in a report on Tuesday, November 4th. HC Wainwright cut their price target on shares of TScan Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, November 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley lowered shares of TScan Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Friday, November 14th. Finally, Needham & Company LLC cut their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $6.60.
Get Our Latest Stock Analysis on TCRX
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in TCRX. Hsbc Holdings PLC acquired a new position in TScan Therapeutics in the 1st quarter valued at $49,000. Checkpoint Capital L.P. increased its position in shares of TScan Therapeutics by 14.9% in the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after purchasing an additional 261,663 shares during the period. BVF Inc. IL increased its position in shares of TScan Therapeutics by 63.6% in the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock worth $6,747,000 after purchasing an additional 1,900,000 shares during the period. Goldman Sachs Group Inc. raised its stake in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after purchasing an additional 9,676 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in TScan Therapeutics by 149.4% during the first quarter. Deutsche Bank AG now owns 52,559 shares of the company's stock worth $73,000 after purchasing an additional 31,481 shares during the period. 82.83% of the stock is owned by institutional investors.
TScan Therapeutics Company Profile
(
Get Free Report)
TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.
The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
